UK-based DaltonTx has launched its Dalton drug discovery platform and announced Sygnature Discovery as its first named CRO client, marking the public commercial debut of an agentic AI system built by scientists with backgrounds at AstraZeneca and Exscientia. The platform, founded on University of Oxford research, is designed to link molecules, assays, models, experimental outcomes, and human decisions into a single self-learning system across both small molecule and biologics programmes. Financial terms were not disclosed.
The Dalton platform operates as a continuous learning engine, described by DaltonTx as capturing not only what happened during a discovery cycle but why a particular scientific path was chosen. Agents propose strategies, evaluate trade-offs, and autonomously orchestrate AI, physics-based, and machine learning tools within conversational workflows. The architecture is intended to compound organisational memory across programmes over time, distinguishing it from single-task generative chemistry tools.
Sygnature Discovery, a UK-based integrated drug discovery CRO with more than 700 scientists operating across Europe and North America, is adding Dalton to an existing computational toolkit that already includes its proprietary SygDesign platform, BullFrog AI, and Iktos. The collaboration is not replacing existing tools but layering an additional agentic reasoning layer across Sygnature's medicinal chemistry workflows. As part of the engagement, Sygnature is conducting a retrospective evaluation using a legacy oncology programme whose small molecule clinical candidate has reached Phase I development, assessing whether the platform could have reached candidate selection more efficiently.
A notable structural feature of the arrangement is the data governance architecture. Sygnature confirmed that customer data and AI models are compartmentalised on a per-programme basis, preventing information from one client's project from informing models used in other projects. For a CRO operating across more than 200 active projects with no competing internal programmes, this separation is a prerequisite for commercial deployment rather than an optional feature.
DaltonTx was founded on research from the University of Oxford and built by a team with prior experience at AstraZeneca and Exscientia. The Sygnature collaboration is the company's second publicly announced partnership in under two weeks. DaltonTx previously partnered with Bonito Biosciences on agentic AI for CNS-targeted oligotherapeutics delivery, combining Bonito's giga-scale encoded ligand libraries with DaltonTx's adaptive AI systems to design delivery ligands for conjugated oligonucleotide payloads.